EPDR1 is a noncanonical effector of insulin-mediated angiogenesis regulated by an endothelial-specific TGF-β receptor complex

Received for publication, February 17, 2022, and in revised form, July 5, 2022. Published, Papers in Press, July 21, 2022, https://doi.org/10.1016/j.jbc.2022.102297

Tasmia Ahmed†, Paola Cruz Flores ‡, Christopher C. Pan⊥, Hannah R. Ortiz ⊥, Yeon S. Lee ⊥, Paul R. Langlais⊥, Karthikeyan Mythreye⊥,⊥,⊥,⊥,⊥ and Nam Y. Lee⊥,⊥⊥,⊥⊥⊥

From the 1Department of Chemistry & Biochemistry, University of Arizona, Tucson, Arizona, USA; 2Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA; 3Department of Pharmacology, and 4Department of Medicine, University of Arizona, Tucson, Arizona, USA; 5Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA; 6Comprehensive Cancer Center, University of Arizona, Tucson, Arizona, USA

Edited by Qi-Qun Tang

Insulin signaling in blood vessels primarily functions to stimulate angiogenesis and maintain vascular homeostasis through the canonical PI3K and MAPK signaling pathways. However, angiogenesis is a complex process coordinated by multiple other signaling events. Here, we report a distinct crosstalk between the insulin receptor and endoglin/activin receptor-like kinase 1 (ALK1), an endothelial cell–specific TGF-β receptor complex essential for angiogenesis. While the endoglin–ALK1 complex normally binds to TGF-β or bone morphogenetic protein 1 (BMP9) to promote gene regulation via transcription factors Smad1/5, we show that insulin drives insulin receptor oligomerization with endoglin–ALK1 at the cell surface to trigger rapid Smad1/5 activation. Through quantitative proteomic analysis, we identify ependymin-related protein 1 (EPDR1) as a major Smad1/5 gene target induced by insulin but not by TGF-β or BMP9. We found endothelial EPDR1 expression is minimal at the basal state but is markedly enhanced upon prolonged insulin treatment to promote cell migration and formation of capillary tubules. Conversely, we demonstrate EPDR1 depletion strongly abrogates these angiogenic effects, indicating that EPDR1 is a crucial mediator of insulin-induced angiogenesis. Taken together, these results suggest important therapeutic implications for EPDR1 and the TGF-β pathways in pathologic angiogenesis during hyperinsulinemia and insulin resistance.

Transforming growth factor β (TGF-β) is a multifunctional cytokine that affects nearly every aspect of mammalian physiology starting from embryogenesis and tissue differentiation to adult homeostasis (1, 2). It plays an essential role in angiogenesis during embryonic development mediated in large part by endoglin, an endothelial cell (EC)–specific coreceptor that binds TGF-β and presents it to the signaling kinase receptor, ALK1, which in turn induces proangiogenic effects through Smad1/5-dependent transcriptional responses (3–6). In the absence of endoglin expression, TGF-β signals mainly through ALK5, a ubiquitously expressed receptor kinase that promotes Smad2/3-dependent cell growth arrest and vascular quiescence (7, 8). Given these specialized angiogenic functions, endoglin and ALK1 are viewed as particularly effective vascular targets to complement the inhibition of vascular endothelial growth factor receptor (VEGFR) signaling in a broad range of clinical applications including tumor growth, diabetic retinopathy, and age-related macular degeneration (5, 9–11).

Insulin is a primary regulator of glucose metabolism but also has a central role in angiogenesis and hemodynamics (12, 13). In ECs, insulin binding to the insulin receptor (IR) induces the downstream PI3K/Akt and MAPK pathways to enhance survival mechanisms while promoting nitric oxide (NO) production, cell proliferation, and vascular permeability (12–18). These proangiogenic effects have been demonstrated in various in vitro and in vivo models, although the underlying molecular mechanisms have yet to be fully established. There are several outstanding questions regarding IR signaling in the endothelium including how it spatiotemporally coordinates the VEGF-dependent and VEGF-independent mechanisms during sprouting angiogenesis, and perhaps more important, why IR signaling is critically important when in fact its canonical PI3K/Akt and MAPK pathways can be theoretically compensated by many other receptor tyrosine kinases including VEGFR2 and insulin-like growth factor 1 receptor (IGF-1R) (5, 10, 19, 20).

In defining new roles of insulin/IR signaling in the vasculature, here we report a direct crosstalk between the IR and the endoglin–ALK1 complex critical for angiogenesis. We find that insulin can signal though endoglin–Alk1 in ECs to trigger Smad1/5 transcriptional activation. Through quantitative proteomics, we identify ependymin-related protein 1 (EPDR1) as a powerful downstream gene target uniquely responsive to insulin but not TGF-β or BMP9. Moreover, we present molecular and cellular evidence of the underlying crosstalk mechanisms and the previously unknown role of EPDR1 in endothelial functions.

* For correspondence: Nam Y. Lee, namlee@email.arizona.edu; Karthikeyan Mythreye, mkarthikeyan@uabmc.edu.
**Insulin induces TGF-beta signaling during angiogenesis**

**Results**

**Insulin induces rapid Smad1/5 activation in vascular ECs**

Previous studies have established important links between insulin and TGF-β signaling, most notably recent findings showing that insulin increases TGF-β responsiveness by promoting the cell surface retention of the TGF-β receptors (ALK5 and TβRII) (21, 22). While such effects were Akt dependent and caused Smad2/3 activation in diverse cell types including ECs (23), we sought an alternative mechanism specifically involving endoglin that could potentially explain why insulin causes Smad1/5 activation in vascular ECs. Indeed, we unexpectedly observed that insulin triggers Smad1/5 activation in both a dose-dependent and endoglin-dependent manner as evidenced by the increased Smad1/5 phosphorylation in control (Eng+/+) but not endoglin KO (Eng−/−) mouse embryonic ECs (MEECs) (Fig. 1A; graph). This induction was rapid with a discernable increase in phosphorylation occurring within 5 min of stimulation and reaching maximum levels upon 15 to 30 min before gradually decreasing over the course of 2 to 4 h (Fig. 1B; graph, Fig. S1A). To test whether endoglin directly mediates this response, we ectopically restored endoglin expression in Eng−/− ECs to find a distinct endoglin-dependent Smad1/5 phosphorylation upon insulin treatment, suggesting that endoglin is required for insulin-induced Smad1/5 phosphorylation (Fig. 1C). Finally, to test whether this effect is observed in other EC types, we chose a human microvascular EC (HMEC1) to assess whether Smad1/5 activation occurs in response to insulin in an endoglin-dependent manner. Similar to the MEECs, there was a rapid increase in Smad1/5 phosphorylation in control cells but not upon stable knockdown of endoglin expression (sh-Eng) (Fig. S1, B and C), thus demonstrating that endoglin mediates insulin-induced Smad1/5 phosphorylation in vascular ECs.

Because Smad1/5 phosphorylation causes their nuclear translocation for gene regulation (24), we next evaluated the effects of insulin on Smad1 subcellular localization. To do so, endoglin expression was ectopically restored in Eng−/− cells

![Image](image-url)
and then stimulated with insulin for 30 min prior to fixation for immunofluorescence (IF) analysis. At basal state, less than 10% of the Eng−/− cell population displayed Smad1 nuclear accumulation compared to roughly 30% in those transiently expressing endoglin (Fig. 1D; graph). However, insulin treatment caused markedly increased Smad1 translocation to nearly 80% in endoglin-positive cell populations compared to no change observed in endoglin-deficient ECs (Fig. 1D; graph). Together, these results indicated that the insulin-induced Smad1/5 activation and nuclear translocation strictly requires endoglin expression.

**Insulin promotes endoglin/IR interaction at the cell surface**

Since insulin is capable of binding IR and IGF-1R (12, 18), we first tested whether IR is the primary mediator of Smad1/5 activation by generating a stable IR knockdown in MEECs (sh-IR; Fig. S2A). Subjecting these cells to insulin treatment showed impaired Smad1/5 phosphorylation over a broad range of insulin concentrations relative to control (Fig. S2B), thus indicating that insulin signals through IR. Based on this finding, we explored the possibility of a physical interaction between endoglin and IR.

To do so, we initially overexpressed hemagglutinin (HA)-tagged endoglin and IR in COS7 cells prior to immunoprecipitation (IP) with an HA-antibody and observed their robust co-IP only when expressed together but not when IR was expressed alone (Fig. 2A). Because endoglin often exists in a complex with ALK1, the signaling receptor that phosphorylates Smad1/5, we next tested whether IR also interacts with ALK1. Here, Myc-tagged ALK1 was ectopically expressed in COS7 cells subsequently used as a bait by immobilizing it on an anti-Myc bead column. A pull down was then performed in which separately prepared cell lysates containing the ectopic expression of endoglin alone, IR alone, or endoglin and IR (Fig. 2B). Notably, results showed that ALK1 associated with IR only when endoglin was present, thus suggesting that endoglin acts as a crucial mediator in this novel ALK1–IR–endoglin complex. This trimeric interaction was further tested in an endogenous setting by using MEECs where endoglin IP resulted in the co-IP of endogenous ALK1, as well as basal interaction with endogenous IR (Fig. 2C). However, the basal endoglin/IR interaction was markedly enhanced when cells were briefly treated with insulin before the IP, whereas the endoglin–ALK1 interaction remained unchanged (Fig. 2C; third panel), suggesting that insulin augments the physical interaction between IR and the endoglin–ALK1 complex at the EC surface. To test this possibility, a cell surface biotinylation assay was performed on control and Eng−/− MEECs upon brief treatment with increasing concentrations of insulin prior to endoglin IP to assess for changes in cell surface endoglin/IR interactions (Fig. 2D). Here, we found that the biotinylated IR fractions coprecipitating with endoglin IP rose accordingly with increasing insulin concentrations, whereas no such detections were observed in Eng−/− ECs, thus supporting that insulin drives the cell surface endoglin-IR interaction in ECs (Fig. 2D).

Consistent with the aforementioned results, IF analysis revealed a distinct colocalization of endoglin and IR along the cell membrane when transiently coexpressed in Eng−/− ECs (Fig. 2E; white arrows and graph). As assessed by Pearson’s correlation, insulin treatment only further enhanced their colocalization along the membrane but not in the cytoplasm, thus supporting a clear role of insulin in enhancing the endoglin/IR interaction at the cell membrane to activate Smad1/5 downstream.

**Insulin activates Smad1/5 through PI3K/Akt- and ERK-independent IR-Src signaling axis**

Since insulin primarily activates the PI3K/Akt and ERK/MAPK pathways in ECs (12, 15, 18), we tested whether these prominent effectors are involved in Smad1/5 phosphorylation by using pharmacologic inhibitors of PI3K, Akt, and ERK. Importantly, while insulin proved capable of activating Smad1/5 as robustly as our positive control, BMP9, pretreatment of cells with a PI3K inhibitor had no effect on Smad1/5 phosphorylation (Fig. 3A; lanes 2 versus 4). Similarly, pretreatment of cells with a pan-Akt inhibitor, which blocks the Akt kinase activity irrespective of its phosphorylation level at S473, had negligible effect on insulin-dependent Smad1/5 induction (Fig. 3A; lane 3). But LDN193189, an inhibitor of the BMP pathway that demonstrates high selectivity for ALK1 at low concentrations (25), completely abrogated insulin-induced Smad1/5 phosphorylation, thus demonstrating that insulin requires IR, endoglin, and the ALK1 kinase to stimulate Smad1/5 phosphorylation (Fig. 3A; graph). To further show that insulin-induced Smad1/5 phosphorylation directly occurs through ALK1, we overexpressed a kinase-dead ALK1 point mutant (ALK1K221R), which exerted a dominant negative effect of abolishing Smad1/5 activation relative to control (Fig. S2C). Next, we tested how MEK inhibition, which blocks the downstream ERK activation, affects insulin-induced Smad1/5 phosphorylation (26). As is shown in Figure 3B, MEK inhibition failed to prevent Smad1/5 phosphorylation, whereas it effectively blocked ERK activation (Fig. 3B; panel 1 versus 3, and graph), thus suggesting that insulin-IR signals through a pathway other than the canonical PI3K/Akt and ERK pathways.

To determine whether the insulin-induced IR kinase activity and downstream IRS1/2 activation are involved in Smad1/5 phosphorylation, the IR tyrosine autophosphorylation and IRS1/2-activation were assessed in Eng+/+ and Eng−/− ECs (Fig. S3). Here, we noted that IR tyrosine phosphorylation levels were similar in both cell types in response to insulin stimulation (Fig. S3A), as was the activation of the downstream insulin receptor substrate (IRS) 1/2 upon insulin treatment, although surprisingly the basal tyrosine (Y612) phosphorylation level was greater in Eng−/− ECs (Fig. S2B). But notably, because the insulin-induced activation of IR/IRS1/2 in endoglin-null cells was nevertheless comparable to the WT ECs and yet incapable of causing Smad1/5 phosphorylation, these data suggested that IRS1/2 is not directly responsible for this effect. However, a previous study has shown that insulin stimulates the IR recruitment of the Src kinase, which in turn,
promotes the tyrosine phosphorylation of IR as well as downstream signaling (27). Hence, we explored whether Src is involved in this process by using PP2, a broad-spectrum inhibitor of Src family kinases (27), and discovered that PP2 treatment completely blocked insulin-induced Smad1/5 activation compared to Akt and PI3K-specific inhibitors (Fig. 3C; graph), indicating that the insulin-IR signaling axis requires Src activity to stimulate the endoglin/ALK1 complex for Smad1/5 phosphorylation.

Several studies have reported an important crosstalk between Src and TGF-β signaling, particularly in relation to the...
role of TβRII (28–31). Because the endoglin–ALK1 complex requires TβRII to activate Smad1/5 in response to TGF-β but not BMP9, we examined whether TβRII is involved in Src-dependent Smad1/5 activation in response to insulin (Fig. S3C). Here, we observed that TβRII overexpression failed to enhance the insulin-induced Smad1/5 phosphorylation, thus suggesting that TβRII is not essential for this process.

**Quantitative proteomics analysis of insulin treated Eng+/+ and Eng−/− MEECs**

To identify proteins responsive to insulin-induced Smad1/5 activation associated with endoglin, we performed unbiased quantitative proteomics analysis on Eng+/+ and Eng−/− MEECs treated with insulin for 16 h (Figs. 4A and S4). Volcano plot analysis of all 7000-plus proteins identified in the quantitative proteomics experiment highlighted the finding that the loss of endoglin significantly alters insulin-induced protein expression changes within the MEECs, supporting the hypothesis that endoglin mediates transcriptional activation/repression within MEECs in response to insulin (Fig. 4B).

Unbiased hierarchical clustering and accompanying heat map visualization of a subset of the significantly affected proteins revealed that endoglin deletion results in both losses (329) and gains (482 proteins) in protein abundance relative to control (Fig. 4C), while gene ontology analysis of this group of significantly affected proteins (811) identified the highest enrichment in biological processes associated with angiogenesis, wound healing, actin filament organization, and cell migration (Fig. 4D), most of which can strongly influence cell migration, differentiation, and capillary morphogenesis during angiogenesis. Among the top statistically significant responders, ependymin-related 1 (EPDR1) was found to be highly upregulated in Eng+/+ cells with a 13-fold increase compared to Eng−/− MEECs (Fig. S4B).

**EPDR1 is a gene target of insulin-induced Smad1/5 activation**

EPDR1 is a cell adhesion molecule structurally related to protocadherins and ependymins (32–35), although this protein has never been associated with insulin/IR or TGF-β/Smad signaling. Therefore, we first validated our quantitative proteomics results through immunoblotting where Eng+/+ cells showed more than 3-fold increase in basal and nearly 13-fold increase in insulin-stimulated expression of EPDR1 compared to Eng−/− MEECs (Fig. S4A; graph), thus confirming that this cell adhesion protein is a Smad1/5 gene target controlled by insulin. However, neither TGF-β- or BMP9-induced Smad1/5 activity was able to enhance EPDR1 expression relative to basal levels (Fig. S4B; graph), suggesting that EPDR1 is specifically an insulin-induced Smad1/5 gene target coordinated by the endoglin–ALK1–IR complex.

To test whether Smad1/5 are involved in insulin-induced EPDR1 expression, we generated stable Smad1 knockdown MEECs (sh-Smad1) (Fig. S5A) and assessed their ability to control EPDR1 expression (Figs. 5C and S5B). In response to
insulin, scramble control ECs displayed a striking upregulation of EPDR1 expression relative to control or even TGF-β and BMP9, whereas the expression proved minimal in sh-Smad1 cells regardless of ligand treatment (Fig. 5C; graph). Together, these findings confirm that EPDR1 is a newly identified Smad1 gene target selectively regulated by insulin. Insulin-induced EPDR1 expression promotes EC migration and endothelial capillary tubule formation

EPDR1 function remains poorly characterized, although it has been recently shown to modulate cell migration and invasion of cancer cells (32, 35). Given its new link to insulin and Smad1/5 signaling, we began our investigation by stably knocking down EPDR1 in Eng+/+ ECs (Fig. S6A). IF analysis showed that EPDR1 was localized primarily as perinuclear clusters that became more pronounced upon insulin stimulation, whereas stable knockdown cells displayed minimal signal (Fig. S6B; red). Next, we explored the role of EPDR1 in EC migration and angiogenesis by performing scratch wound healing and Boyden transwell assays to measure collective and single cell migration, respectively. To first determine how insulin affects EC motility in our system, we compared Eng+/+ versus Eng−/− MEECs under serum-deprived conditions in the presence or absence of insulin (Fig. 6A). Here, Eng+/+ cells displayed strong responsiveness to insulin as evidenced by the increased migration relative to control, whereas Eng−/− cells generally showed lower migration independent of insulin treatment (Fig. 6A, graph). In parallel experiments using EPDR1 knockdown Eng+/+ ECs, the migratory responses were all comparable to control at basal conditions but were sharply reduced (~2.5-fold) in response to insulin (Figs. 6B and S6C; graphs). Similar patterns on cell motility were observed for these cells using the
Boyden chamber studies (Fig. S7), thus supporting the notion that endoglin-dependent EPDR1 upregulation in response to insulin promotes EC migration.

Further consistent with the aforementioned conclusion, EPDR1-depleted ECs showed similar potential to form capillary-like tubules in Matrigel at basal conditions unlike Eng−/− ECs but notably failed to promote capillary branching in response to insulin when compared to control ECs (Fig. 6C; graph). Together, these results indicate that EPDR1 is a previously unknown effector of insulin signaling critical for angiogenesis and mediated by IR crosstalk with the endoglin–ALK1 receptor system in vascular ECs.

Discussion

Our present work identifies an important crosstalk between IR and an endothelial TGF-β receptor complex that begins at the cell surface and culminates with the expression of EPDR1 as one of the major Smad1/5 gene targets critical for angiogenesis (Fig. 6D). This new signaling axis fundamentally differs from a previously proposed mechanism in which insulin increases TGF-β responsiveness by enhancing the delivery of TβRII and ALK5 to the cell surface, a widely expressed TGF-β receptor complex that activates the Smad2/3 pathway (22).

Several important mechanistic distinctions are noted between the insulin-induced activation of Smad2/3 versus Smad1/5. First, Smad2/3 activation still requires autocrine TGF-β signaling (22), whereas in the endothelial system, insulin itself appears to be the major driver of Smad1/5 activation through oligomerization of IR and endoglin–ALK1 at the membrane. We conclude that TGF-β does not play a significant role in this new signaling axis since Smad1/5 is rapidly activated by insulin (4–6 h). Second, insulin-dependent Smad2/3 induction appears to be mediated by Akt, which in turn promotes AS160 activation (22), an endosomal membrane trafficking protein known to promote the translocation of many transmembrane proteins to the cell surface (36–40). Our data, in contrast, demonstrate that the PI3K/Akt pathway is dispensable for Smad1/5 activation, and instead, requires insulin-IR-dependent Src activation (Fig. 3).

It is unclear how Src is involved in Smad1/5 phosphorylation, although it is plausible that Src enhances the activation of the ALK1 kinase through phosphorylation. Our efforts to identify potential Src-dependent tyrosine phosphorylation sites on ALK1 proved unsuccessful by mass spectrometry (MS) due to insufficient peptide coverage (data not shown), but nevertheless, this does not exclude the possibility that ALK1 is directly involved since its kinase activity appears to be
essential. Previous studies have shown that Src is critical for TβRII activation—a process involving Tyr284 phosphorylation that mediates TGF-β-dependent mammary tumor growth and metastasis (28, 29). However, TβRII phosphorylation by Src reportedly had no effect on Smad activity, an observation consistent with our data indicating that TβRII is not essential for insulin-induced Smad1/5 phosphorylation. Instead, Src may modulate the activity of other ALK1 effectors such as CK2β, which we previously showed to directly interact with and promote ALK1 signaling in a phosphorylation-independent manner (41). While beyond the scope of the present study, precisely how the insulin-IR signaling axis mediates ALK1 activation through Src remains an important question to address to fully understand the role of insulin-Smad1/5 signaling during angiogenesis.

It is noteworthy that insulin-induced Smad1/5 activation drives EPDR1 expression but not TGF-β or BMP9 since they are both strong activators of this transcriptional pathway in the vascular system. However, while TGF-β and BMP9 can both regulate the same gene targets through Smad1/5 in ECs, distinct transcriptional responses have also been reported previously. For instance, BMP9 is thought to be a much more selective activator of ID1 transcription than TGF-β (5). A similar ligand-specific effect may be in play here where Smad1/5 couples with other insulin-dependent cofactors to recognize insulin-responsive gene elements.

There are several disease implications from our findings, chief among which is that vascular disorders arising from hyperinsulinemia may be perceived as not only an insulin signaling problem but one that also involves the TGF-β pathways. Indeed, while research has shown that hyperinsulinemia mediates pathologic angiogenesis through the proliferative actions of the ERK MAPK pathway (42, 43), chronically elevated levels of insulin may also trigger the expression of EPDR1 and potentially many others through the endoglin/ALK1/Smad1/5 signaling axis. For instance, chondroitin sulfate synthase 2 (44, 45) and prostaglandin F2 receptor-associated protein (46–48) are two of the top hits ranked higher than EPDR1, whereas others, including osteopontin (49, 50) and platelet-derived growth factor receptor beta (51, 52), represent promising candidates ranked slightly lower based on several parameters including fold changes over negative control and unique peptide counts identified (Fig. S3B). Future studies could explore whether these protein factors can serve as unique vascular targets during pathologic angiogenesis such as in diabetic retinopathy (53–57).

In summary, we conclude that EPDR1 is a crucial mediator of insulin-induced angiogenesis. Its Smad1/5-induced
expression is driven by a direct crosstalk between IR and endoglin–ALK1, a process that occurs in activated ECs of angiogenic vessels. These findings unveil important therapeutic implications for EPDR1 and the TGF-β pathways in pathologic angiogenesis during hyperinsulinemia and insulin resistance.

Experimental procedures

Cell culture, plasmid, and transfection

Endoglin-null (Eng/−/−) and control (Eng+/+) ECs were derived from WT and endoglin KO mice at E9 as previously described (58). MEECs were grown in MCDB-131 supplemented with 10% fetal bovine serum (FBS) (Gibco), 2 mM l-glutamine, 1 mM sodium pyruvate (Invitrogen), 100 μg of heparin (Sigma), and 50 μg/ml endothelial cell growth supplement (Sigma). Cells were cultured in flasks coated with 0.05% gelatin. COS-7 cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% FBS (Gibco). Transfections were achieved by using Lipofectamine 2000 as described according to manufacturer’s protocol (Invitrogen). The HA-tagged endoglin construct was reported previously (59). GFP-tagged human IR (IR-β) was acquired from Addgene (plasmid #22286).

Reagents and antibodies

Matrigel matrix was obtained from Corning. Insulin, human recombinant, zinc solution was purchased from Thermo Fisher Scientific. TGF-β1 and BMP-9 were obtained from R&D Systems. Inhibitors of ALK1 (LDN193189), PI3K inhibitor (LY294002), Src family inhibitor (PP2), and MEK inhibitor (PD98059) were obtained from Sigma–Aldrich. Pan-Akt inhibitor (GSK690693) was purchased from Selleckchem. The following antibodies were all purchased from Cell Signaling: P-Smad1/5/9, Smad1, P-Akt serine 473, P-p42/44 MAPK, Src, and IR. β-actin was purchased from Sigma–Aldrich, anti-HA was from Roche, and Endoglin (P3D1), Endoglin (A-8), ALK1, and EPDR1 antibodies were purchased from Santa Cruz Biotechnology.

Protein expression and knockdowns

The shRNA constructs for mouse Smad1 and EPDR1 were purchased from Sigma. The shRNA targeting sequences for mouse Smad1 were as follows: 5’- TCCTATTTCATCGGTGCTCTTA-3’ and 5’-TGCTGCCTCATATTGTGT-TACTAT-3’. The shRNA for mouse EPDR1 was lentiviral transduction particles and the shRNA targeting sequences were as follows: 5’-GCGTTTATACAGCCAAGGATT-3’ and 5’-CAGCCACGATGTGCAAAGAT-3’. Smad1 knockdown was generated by transfecting each mouse shRNA constructs into Eng+/+ ECs using Lipofectamine 2000. EPDR1 knockdown (sh-EPDR1) was achieved by infecting EPDR1 shRNA lentiviral particles into Eng+/+ ECs using 5 μg/ml Polybrene in regular growth media. For both Smad1 and EPDR1, stable knockdown was achieved by selecting with puromycin (5–10 μg/ml). Individual puromycin-resistant colonies were picked and scaled up as individual clones upon biochemical validation of endogenous >80% Smad1 depletion. Level of knockdown was tested comparing its endogenous protein level with that of scrambled control cells. Scramble control cells were transfected with scrambled control shRNA plasmid and were also selected with puromycin (5–10 μg/ml).

Cell surface biotinylation

Cells were treated with or without insulin at various concentrations (0, 50, 100, 200, and 500 nM) for 10 min prior to being washed with PBS, then treated with 0.5 mg/ml biotin-LC (Pierce) on ice for 15 min. Upon extensive washes with PBS, cells were lysed with lysis buffer (20 mm Hepes, pH 7.4, 150 mM NaCl, 0.5% NP-40, 2 mM EDTA, 10 mM NaF, and 10% w/v glycerol) supplemented with protease and phosphatase inhibitor cocktails (Sigma), lysates were normalized for total protein content via Bradford, and then were immunoprecipitated with A8 antibody. All biotinylated proteins were resolved by SDS-PAGE and probed with streptavidin-horseradish peroxidase, A8, and IR antibodies.

Western blotting

Western blotting cell lysates were separated by SDS-PAGE and electrophoretic transferred onto the polyvinylidene difluoride membranes (Bio-Rad). Transferred membranes were blocked with 5% milk in Tris-buffered saline with Tween-20 (TBS-T) and then incubated with primary antibodies at 4 °C overnight. Following day, membranes were washed 3x in TBS-T buffer and incubated with the secondary antibody for 45 min at room temperature (RT). Membranes were washed 5x in TBS-T each for 5 min, then imaged by ChemiDoc Imaging system (Bio-Rad).

IF microscopy

Cells grown on coverslip that were washed with PBS, fixed with 4% paraformaldehyde, permeabilized in 0.1% Triton X-100/PBS for 5 min, and then blocked with 5% bovine serum albumin in PBS containing 0.05% Triton X-100 for 1 h. Cells were incubated with appropriate primary and fluorophore-conjugated secondary antibodies for 1 h at RT, washed, and then mounted with ProLong Antifade (Sigma).

Transwell migration assay

Eng+/+, Eng−/−, or sh-EPDR1 MEECs were serum starved for 5 h and then plated in serum-free MCDB131 media
Insulin induces TGF-beta signaling during angiogenesis

containing 2 mM L-glutamine in the presence or absence of insulin. Cells were seeded in the upper chamber of the transwells (Costar Corning Inc, 8 μM polycarbonate membrane 6.5 mm insert, 24-well plate), which were coated with 0.02% gelatin prior to plating. The bottom wells were filled with MCD8131 media containing 10% FBS. Cells were allowed to migrate for 16 h prior to cell fixation and staining of the nuclei of the migrated cells on the bottom side of the membrane. The transwell membrane containing the stained migrated cells were digitally imaged in three random fields per well and counted using Imagej software (https://imagej.nih.gov/ij/) to tabulate cells as they were manually identified.

Wound scratch assay

Eng+/+, Eng−/−, or sh-EPDR1 MEECs were seeded in 6-well plates and grown to confluence in complete growth medium prior to scratch induction using a 200 μl pipette tip. The cells were washed 2× with PBS, then treated with or without insulin in serum-free media containing 2 mM L-glutamine for 16 h. Images of the open wound were taken immediately after adding the insulin treatment in the open wound and again after 16 h to photograph the wound closure by the migrated cells over time. For quantification, three measurements of each monolayer sample were taken in three independent wounds per sample.

Endothelial tube formation

96-well plates were coated with Matrigel (Corning) and incubated at 37 °C for 30 min. Following Matrigel polymerization, Eng+/+, Eng−/−, or sh-EPDR1 MEECs were seeded in serum-free media containing 2 mM L-glutamine in the presence or absence of insulin and were grown for 16 h. For each well, three microscope fields were selected randomly and were photographed digitally. Capillary branches were counted in each field. Experimental condition was normalized as percentage compared to WT cells with no treatment.

In-gel tryptic digestions, MS, database searching, and quantitative proteomics

In-gel tryptic digestion and HPLC-electrospray ionization-MS/MS was performed exactly as previously described (60, 61). Tandem mass spectra were extracted from Xcalibur ‘RAW’ files and charge states were assigned using the ProteoWizard 3.0 msConvert script using the default parameters. The fragment mass spectra were searched against the Mus musculus SwissProt_2018_01 database (16,965 entries) using Mascot (Matrix Science; version 2.6.0) using the default probability cut-off score. The following search variables were used: 10 ppm mass tolerance for precursor ion masses and 0.5 Da for-product ion masses; digestion with trypsin; a maximum of two missed tryptic cleavages; variable modifications of oxidation of methionine and phosphorylation of serine, threonine, and tyrosine. Crosscorrelation of Mascot search results with X! Tandem was accomplished with Scaffold (version Scaffold_4.8.7; Proteome Software). Probability assessment of peptide assignments and protein identifications were made using Scaffold. Only peptides with ≥95% probability were considered. Progenesis QI for proteomics software (version 2.4, Nonlinear Dynamics Ltd) was used to perform ion intensity–based label-free quantification as previously described (62).

Data availability

Raw MS data will be available upon request.

Supporting information—This article contains supporting information.

Acknowledgments—We would like to thank the University of Arizona Cancer Center for their assistance.

Author contributions—K. M. and N. Y. L. conceptualization; H. R. O., P. R. L., K. M., and N. Y. L. formal analysis; T. A., P. C. F., C. C., and N. Y. L. writing—original draft; K. M. and N. Y. L. writing—review & editing.

Funding and additional information—This work was supported in part by NIH grant GM128055 awarded to N. Y. L., the University of Arizona Cancer Center internal funding, and the Cancer Center Support Grant (P30 CA023074). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: EC, endothelial cell; FBS, fetal bovine serum; HA, hemagglutinin; IF, immunofluorescence; IP, immunoprecipitation; IR, insulin receptor; IRS, insulin receptor substrate; MEEC, mouse embryonic EC; MS, mass spectrometry; TBS-T, Tris-buffered saline with Tween-20.

References

1. Gordon, K. J., and Blobe, G. C. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 1782, 197–228
2. Blobe, G. C., Schiemann, W. P., and Lodish, H. F. (2000) Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342, 1350–1358
3. Lebrin, F., Goumans, M. J., Jonker, L., Carvalho, R. L., Valdimarsdottir, G., Thorikay, M., et al. (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 23, 4018–4028
4. Lee, N. Y., Golzio, C., Gatza, C. E., Sharma, A., Katsanis, N., and Blobe, G. C. (2012) Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol. Biol. Cell 23, 2421–2432
5. Scharpenecker, M., van Dinther, M., Liu, Z., van Besouw, R. L., Zhao, Q., Pukac, L., et al. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964–972
6. Blanco, F. J., Santibanez, J. F., Guerrero-Esteo, M., Langa, C., Vary, C. P., and Bernabeu, C. (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell Physiol. 204, 574–584
7. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and ten Dijke, P. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21, 1743–1753
MAPK during breast cancer cell proliferation and invasion. Cancer Res. 67, 3752–3758
30. Maeda, M., Shintani, Y., Wheelock, M. J., and Johnson, K. R. (2006) S6c activation is not necessary for transforming growth factor (TGF)-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. Pp1 directly inhibits TGF-beta receptors I and II. J. Biol. Chem. 281, 59–68
31. Galliher, A. J., and Schiemann, W. P. (2006) Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 8, R42
32. Yang, Y., Zhang, H., Liu, Z., Zhao, F., and Liang, G. (2021) EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker. BMC Urol. 21, 71
33. Nakatsukasa, K., Nishimura, T., Byrne, S. D., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., et al. (2015) The ubiquitin ligase SCFvcl1 acts as a metabolic switch for the glyoxylate cycle. Mol. Cell. 57, 22–34
34. Ganss, B., and Hoffmann, W. (2009) Calcium-induced conditional transition of t1t pependymins monitored by t1ryptophan fluorescence. Open Biochem. J. 3, 14
35. Gimeno-Valiente, F., Riofo-Campos, A. L., Ayala, G., Tarazona, N., Gambardella, V., Rodriguez, F. M., et al. (2020) EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Sci. Rep. 10, 3723
36. Mlinea, C. P., Sano, H., Kane, S., Sano, E., Fukuda, M., Peränen, J., et al. (2005) AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. Biochem. J. 391, 87–93
37. Thong, T. S., Bilan, P. J., and Klip, A. (2007) The Rab GTPase-activating protein AS160 integrates Akt, protein kinase C, and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 56, 414–423
38. Liang, X., Butterworth, M. B., Peters, K. W., and Frizzell, R. A. (2010) AS160 modulates aldosterone-stimulated epithelial sodium channel forward trafficking. Mol. Biol. Cell 21, 2024–2033
39. Kim, H. Y., Choi, H. J., Lim, J. S., Park, E. J., Jung, H. J., Lee, Y. J., et al. (2011) Emerging role of Akt substrate protein AS160 in the regulation of AQP2 translocation. Am. J. Physiol. Renal Physiol. 301, F151–161
40. Jung, H. J., and Kwon, T.-H. (2010) Membrane trafficking of collecting duct water channel protein AQP2 regulated by Akt/AS160. Electrolytes Blood Press. 8, 59–65
41. Lee, N. Y., Haney, J. C., Sogani, J., and Blobe, G. C. (2009) Casein kinase 2beta as a novel enhancer of activin-like-receptor-1 signaling. FASEB J. 23, 3712–3721
42. Walker, A. M. N., Warmke, N., Mercer, B., Watt, N. T., Mughal, R., Smith, J., et al. (2021) Endothelial insulin receptors promote VEGF-A signaling via ERK1/2 and sprouting angiogenesis. Endocriology 162, bqb104
43. Jiang, Y., He, Z., King, B. L., Kuroki, T., Opland, D. M., Suzuma, K., et al. (2003) Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J. Biol. Chem. 278, 31964–31971
44. Fthenou, E., Zong, F., Zafirooulos, A., Dobra, K., Hjerpe, A., and Tzaknakas, G. N. (2009) Chondroitin sulfate A regulates fibroscaroma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. In Vivo 23, 69–76
45. Chu, Y. H., Liao, W. C., Ho, Y. J., Huang, C. H., Tseng, T. J., and Liu, C. H. (2021) Targeting chondroitin sulfate reduces invasiveness of glioma cells by suppressing CD44 and integrin beta1 expression. Cells 10, 3594
46. Mala, U., Baral, T. K., and Somasundaram, K. (2022) Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene. BMC Cancer 22(642)
47. Baryla, M., Kaczynski, P., Goryszewska, E., Riley, S. C., and Waclawik, A. (2019) Prostaglandin F2a stimulates adhesion, invasion, and proliferation of the human trophoblast cell line HTR-8/SVneo. Placenta 77, 19–29
48. Kaczynski, P., Kowalewski, M. P., and Waclawik, A. (2016) Prostaglandin F2a promotes angiogenesis and embryo-maternal interactions during implantation. Reproduction 151, 539–552
Insulin induces TGF-beta signaling during angiogenesis

49. Huang, R., Quan, Y., Chen, J., Wang, T., Xu, M., Ye, M., et al. (2017) Osteopontin promotes cell migration and invasion, and inhibits apoptosis and autophagy in colorectal cancer by activating the p38 MAPK signaling pathway. *Cell Physiol. Biochem.* **41**, 1851–1864

50. Dai, J., Peng, L., Fan, K., Wang, H., Wei, R., Ji, G., et al. (2009) Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. *Oncogene* **28**, 3412–3422

51. Magnusson, P. U., Looman, C., Ahgren, A., Wu, Y., Claesson-Welsh, L., and Heuchel, R. L. (2007) Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro. *Arterioscler. Thromb. Vasc. Biol.* **27**, 2142–2149

52. Kawada, K., Upadhyay, G., Ferandon, S., Janarthanan, S., Hall, M., Vildarada, J. P., et al. (2009) Cell migration is regulated by platelet-derived growth factor receptor endocytosis. *Mol. Cell. Biol.* **29**, 4508–4518

53. Shen, S., Wang, F., Fernandez, A., and Hu, W. (2020) Role of platelet-derived growth factor in type II diabetes mellitus and its complications. *Diabetes Vasc. Dis. Res.* **17**, 1479164120942119

54. Gong, Q., Chipitsyna, G., Gray, C. F., Anandanadesan, R., and Arafat, H. A. (2009) Expression and regulation of osteopontin in type 1 diabetes. *Islets* **1**, 34–41

55. Qi, S. S., Shao, M. L., Sun, Z., Chen, S. M., Hu, Y. J., Li, X. S., et al. (2021) Chondroitin sulfate alleviates diabetic osteoporosis and repairs bone microstructure via anti-oxidation, anti-inflammation, and regulating bone metabolism. *Front. Endocrinol. (Lausanne)* **12**, 759843

56. Zheng, H. X., Chen, J., Zu, Y. X., Wang, E. Z., and Qi, S. S. (2020) Chondroitin sulfate prevents STZ induced diabetic osteoporosis through decreasing blood glucose, antioxidative stress, anti-inflammation and OPG/RANKL expression regulation. *Int. J. Mol. Sci.* **21**, 5303

57. Ding, W.-Y., Liu, L., Wang, Z.-H., Tang, M.-X., Ti, Y., Han, L., et al. (2014) FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy. *J. Mol. Med.* **92**, 629–640

58. Pece-Barbara, N., Vera, S., Kathirkamathamby, K., Liebner, S., Di Guglielmo, G. M., Dejana, E., et al. (2005) Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. *J. Biol. Chem.* **280**, 27800–27808

59. Lee, N. Y., Ray, B., How, T., and Blob, G. C. (2008) Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. *J. Biol. Chem.* **283**, 32527–32533

60. Kruse, R., Krantz, J., Barker, N., Coletta, R. L., Rafikov, R., Luo, M., et al. (2017) Characterization of the CLASP2 protein interaction network identifies SOGA1 as a microtubule-associated protein. *Mol. Cell. Proteomics* **16**, 1718–1735

61. Parker, S. S., Krantz, J., Kwak, E. A., Barker, N. K., Deer, C. G., Lee, N. Y., et al. (2019) Insulin induces microtubule stabilization and regulates the microtubule plus-end tracking protein network in adipocytes. *Mol. Cell. Proteomics* **18**, 1363–1381

62. Uhlnorn, J. A., Husband, N. A., Romero-Aleshire, M. J., Moffett, C., Lindsey, M. L., Langlais, P. R., et al. (2021) CD4(+) T cell-specific proteomic pathways identified in progression of hypertension across post-menopausal transition. *J. Am. Heart Assoc.* **10**, e018038